BACKGROUND: In vivo evaluation of cholinergic circuits of the human brain has recently been introduced using a transcranial magnetic stimulation (TMS) protocol based on coupling peripheral nerve stimulation with motor cortex TMS (short latency afferent inhibition, SAI). SAI is reduced in Alzheimer's disease (AD) and drugs enhancing cholinergic transmission increase SAI. METHODS: We evaluated whether SAI testing, together with SAI test-retest, after a single dose of the acetylcholinesterase (AChE) inhibitor rivastigmine, might be useful in predicting the response after 1 year treatment with rivastigmine in 16 AD patients. RESULTS: Fourteen AD patients had pathologically reduced SAI. SAI was increased after administration of a single oral dose of rivastigmine in AD patients with abnormal baseline SAI, but individual responses to rivastigmine varied widely, with SAI change ranging from an increase in inhibition of approximately 50% of test size to no change. Baseline SAI and the increase in SAI after a single dose of rivastigmine were correlated with response to long term treatment. A normal SAI in baseline conditions, or an abnormal SAI in baseline conditions that was not greatly increased by a single oral dose of rivastigmine, were invariably associated with poor response to long term treatment, while an abnormal SAI in baseline conditions in conjunction with a large increase in SAI after a single dose of rivastigmine was associated with good response to long term treatment in most of the patients. CONCLUSIONS: Evaluation of SAI may be useful for identifying AD patients likely to respond to treatment with AChE inhibitors.
BACKGROUND: In vivo evaluation of cholinergic circuits of the human brain has recently been introduced using a transcranial magnetic stimulation (TMS) protocol based on coupling peripheral nerve stimulation with motor cortex TMS (short latency afferent inhibition, SAI). SAI is reduced in Alzheimer's disease (AD) and drugs enhancing cholinergic transmission increase SAI. METHODS: We evaluated whether SAI testing, together with SAI test-retest, after a single dose of the acetylcholinesterase (AChE) inhibitor rivastigmine, might be useful in predicting the response after 1 year treatment with rivastigmine in 16 ADpatients. RESULTS: Fourteen ADpatients had pathologically reduced SAI. SAI was increased after administration of a single oral dose of rivastigmine in ADpatients with abnormal baseline SAI, but individual responses to rivastigmine varied widely, with SAI change ranging from an increase in inhibition of approximately 50% of test size to no change. Baseline SAI and the increase in SAI after a single dose of rivastigmine were correlated with response to long term treatment. A normal SAI in baseline conditions, or an abnormal SAI in baseline conditions that was not greatly increased by a single oral dose of rivastigmine, were invariably associated with poor response to long term treatment, while an abnormal SAI in baseline conditions in conjunction with a large increase in SAI after a single dose of rivastigmine was associated with good response to long term treatment in most of the patients. CONCLUSIONS: Evaluation of SAI may be useful for identifying ADpatients likely to respond to treatment with AChE inhibitors.
Authors: V Di Lazzaro; A Oliviero; F Pilato; E Saturno; M Dileone; C Marra; A Daniele; S Ghirlanda; G Gainotti; P A Tonali Journal: J Neurol Neurosurg Psychiatry Date: 2004-04 Impact factor: 10.154
Authors: V Di Lazzaro; A Oliviero; E Saturno; M Dileone; F Pilato; R Nardone; F Ranieri; G Musumeci; T Fiorilla; P Tonali Journal: J Physiol Date: 2005-02-17 Impact factor: 5.182
Authors: Alistair Burns; Andrew Yeates; Latif Akintade; Megan Del Valle; Richard Y Zhang; Elias M Schwam; Carlos A Perdomo Journal: Drugs Aging Date: 2008 Impact factor: 3.923
Authors: Raffaele Nardone; Jürgen Bergmann; Francesco Brigo; Monica Christova; Alexander Kunz; Martin Seidl; Frediano Tezzon; Eugen Trinka; Stefan Golaszewski Journal: J Neural Transm (Vienna) Date: 2012-08-19 Impact factor: 3.575